摘要
骨肉瘤(Osteosarcoma, OS)是一种原发性骨恶性肿瘤,在儿童和青少年中发病率较高。OS受累细胞和组织表现出耐药特性,预后仍较差;因此,迫切需要新的治疗方法。MicroRNAs (miRNAs)表达模式已被证实参与了OS的发病机制。miRNAs是小的非编码RNA分子,在转录后水平负调控基因表达。有大量的miRNAs在疾病的发病、疾病进展的调节和对治疗的反应中具有关键作用。目前,最近发布的Human MicroRNA Disease Database 3.0版本(HMDD v3.0)报告称,OS中有194个miRNAs调控异常,可能参与肿瘤细胞的增殖、迁移、侵袭和上皮-间充质转化。癌基因和抑癌miRNAs之间的平衡对OS细胞行为的最终命运至关重要。此外,在OS的启动或发展过程中,miRNAs网络可能协同作用,诱导致癌或肿瘤抑制特性。这些miRNAs的上调或下调会影响治疗期间或之后的疾病状态。到目前为止,在OS疾病中已经发现了40多个具有致癌或肿瘤抑制特性的miRNAs,研究者正在试图建立一个有利于OS治疗的适当水平的此类miRNAs。miRNAs在骨肉瘤发病机制中的作用及其治疗潜力是本文的参考点。
关键词: 骨肉瘤,MicroRNA,转移,血管生成,靶向治疗,自噬。
Current Molecular Medicine
Title:MicroRNAs Implications in the Onset, Diagnosis, and Prognosis of Osteosarcoma
Volume: 21 Issue: 7
关键词: 骨肉瘤,MicroRNA,转移,血管生成,靶向治疗,自噬。
摘要: Osteosarcoma (OS) is a primary bone malignancy, which has a high incidence in children and adolescents. The affected cells and tissues show the properties of drug-resistance and the prognosis remains poor in OS; therefore, there is an essential need for novel therapeutic approaches. MicroRNAs (miRNAs) expression pattern has been established to be involved in the pathogenesis of OS. miRNAs are small non-coding RNA molecules, which negatively regulate gene expression at the post-transcriptional level. There are copious miRNAs that have a critical role in the onset of the disease, modulation of disease progression, and response to treatment. At the moment, the recently launched version 3.0 of Human MicroRNA Disease Database (HMDD v3.0) reports that 194 miRNAs are dysregulated in OS that might be involved in proliferation, migration, invasion, and epithelial-mesenchymal transition of tumor cells. The balance between oncogene and tumor suppressor miRNAs has vital importance in the final fate of the cell behaviors in OS. Additionally, networks of miRNAs may act in concert to induce oncogenic or tumor-suppressing properties during the initiation or the progression of OS. Up or down-regulation of these miRNAs affect the status of the disease during or after therapy. To date, over 40 miRNAs have been identified in OS disease that possess oncogenic or tumor-suppressing properties, and treatment approaches are trying to establish a proper level of such miRNAs in favor of OS therapy. The role of miRNAs involved in the pathogenesis of OS and their therapeutic potential are the reference points in this review article.
Export Options
About this article
Cite this article as:
MicroRNAs Implications in the Onset, Diagnosis, and Prognosis of Osteosarcoma, Current Molecular Medicine 2021; 21 (7) . https://dx.doi.org/10.2174/1566524020999201203212824
DOI https://dx.doi.org/10.2174/1566524020999201203212824 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Resveratrol and Prostate Cancer: The Power of Phytochemicals
Current Medicinal Chemistry Alterations within the Osteo-Hematopoietic Niche in MDS and their Therapeutic Implications
Current Pharmaceutical Design Endothelial Progenitor Cells: Hope Beyond Controversy
Current Cancer Drug Targets Applications of 211At and 223Ra in Targeted Alpha-Particle Radiotherapy
Current Radiopharmaceuticals The Tumor Suppressor Gene ARF as a Sensor of Oxidative Stress
Current Molecular Medicine Role of Advanced Glycation End Products (AGEs) in Osteoporosis in Diabetes
Current Drug Targets Pharmacogenetics of Phase I and Phase II Drug Metabolism
Current Pharmaceutical Design Persistent GP130/STAT3 Signaling Contributes to the Resistance of Doxorubicin, Cisplatin, and MEK Inhibitor in Human Rhabdomyosarcoma Cells
Current Cancer Drug Targets Carvacrol Suppresses Human Osteosarcoma Cells via the Wnt/β-Catenin Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Novel Orphan Nuclear Receptors-Coregulator Interactions Controlling Anti-Cancer Drug Metabolism
Current Drug Metabolism Development of Genetic Testing for Breast, Ovarian and Colorectal Cancer Predisposition: A Step Closer to Targeted Cancer Prevention
Current Drug Targets VS-5584 Inhibits Human Osteosarcoma Cells Growth by Induction of G1- phase Arrest through Regulating PI3K/mTOR and MAPK Pathways
Current Cancer Drug Targets Artificial Hematopoietic Stem Cell Niche: Bioscaffolds to Microfluidics to Mathematical Simulations
Current Topics in Medicinal Chemistry Exosome-like Nanoparticles: A New Type of Nanocarrier
Current Medicinal Chemistry Therapeutic Potential and Outlook of Alternative Medicine for Osteoporosis
Current Drug Targets Emerging Roles for Modulation of microRNA Signatures in Cancer Chemoprevention
Current Cancer Drug Targets Cyanidin 3-O-Glucoside Induces the Apoptosis in the Osteosarcoma Cells through Upregulation of the PPARγ and P21: An <i>In Vitro</i> Study
Anti-Cancer Agents in Medicinal Chemistry Viral Based Gene Therapy for Prostate Cancer
Current Gene Therapy Meet Our Editorial Board Member
Current Nanomedicine Critical microRNAs in Lung Cancer: Recent Advances and Potential Applications
Anti-Cancer Agents in Medicinal Chemistry